Anxin International's First Coverage Report on China Tobacco Hong Kong

Jun.21.2024
Anxin International's First Coverage Report on China Tobacco Hong Kong
Anxin International released a first coverage report on China Tobacco Hong Kong (6055.HK), predicting strong growth in the future.

On June 21, Anxin International's WeChat public account released the inaugural coverage report on China Tobacco Hong Kong (6055.HK).


The summary of its content is as follows:


China Tobacco Hong Kong (6055.HK) is mainly engaged in tobacco leaf import and export, cigarette export, and new tobacco export business. The company was established in 2004, headquartered in Hong Kong, and serves as the designated overseas platform responsible for capital market operations and international business expansion for China Tobacco International.


The company's performance has continued to grow in recent years. In 23 years, the company's performance has reached a historic high with revenue of 11.8 billion Hong Kong dollars, a year-on-year increase of 42%, and a net profit of 690 million Hong Kong dollars, a year-on-year increase of 49%. The growth is strong. The company has announced a profit forecast, expecting revenue in the first half of the year to increase by no less than 10% and net profit to increase by no less than 30%. The main driving factors behind the performance growth include: 1) the continuous recovery of cigarette export business, leading to a significant increase in revenue and gross profit; 2) the tobacco leaf import business achieving growth in both quantity and price; 3) growth in revenue and gross profit of the tobacco leaf export business. This year, the company's overall development is good, with strong performance growth.


Hong Kong's core competitive advantage lies in its unique franchise rights: the exclusive operation of importing tobacco into the country. It also has exclusive rights to export Chinese tobacco to Southeast Asia, Hong Kong, Macau, and other regions. Additionally, the company exclusively exports domestic cigarette brands in Thailand, Singapore, China Hong Kong, China Macau, and other overseas regions. It also exclusively exports domestic new tobacco brands globally. Benefiting from its exclusive operations status, the company often utilizes back-to-back agreements with customers and suppliers, avoiding transportation, insurance costs, and lower exchange rate risks. With stable demand and supply conditions, the company's profitability is solid. In 21, the company acquired Zhongba Company, further expanding its business footprint through external mergers and acquisitions.


For the tobacco import and export industry, global tobacco production continues to decline, and tobacco prices fluctuate in cycles, currently in an upward cycle. Taking Brazil as an example, one of the main tobacco exporting countries, its tobacco export price decreased from $5.25 per kilogram in 2014 to $3.15 per kilogram in 2021, but rebounded to $4.19 per kilogram in 2022. Due to the influence of the El Niño climate, tobacco production is expected to continue decreasing in 2023, leading to a sustained increase in tobacco prices. The barriers to entry in the tobacco trade industry are high, the market is mature, and trading is relatively stable. China National Tobacco Corporation, along with the four major tobacco companies, hold a global market share of 83%, and for major tobacco traders, the number of clients is limited, as they have already established long-term partnerships. Additionally, traders typically require significant capital investment to control tobacco cultivation.


For cigarette export business, the recovery of passenger flow after the epidemic has driven an increase in sales. In general, global tobacco sales have been declining year by year, but due to the impact of the epidemic in 2020, tobacco consumption has actually been in a stage of recovery growth in recent years. The cigarette export volume of China Tobacco Hong Kong has rebounded rapidly after 2020, which is positively correlated with the number of outbound Chinese tourists. Currently, sales have not fully recovered to the level of 2019, but there is still room for growth. For new types of tobacco exports, the HNB market is growing rapidly, with promising development prospects. By 2023, the HNB market size will reach $34.1 billion, a year-on-year increase of 11.6%. The overall global cigarette market size is $927.4 billion, with the HNB market accounting for only 3.6%, indicating tremendous potential for development.


Overall, we believe that franchising has provided the company with a stable performance base. The rising price of tobacco leaves and the recovery in cigarette exports have both provided growth momentum for the company. In the future, the expansion of new tobacco business and possible mergers and acquisitions will serve as potential growth engines. Taking all factors into account, we anticipate that the company's revenue will reach 13.1/14.4/15.8 billion Hong Kong dollars in 2024/2025/2026, with a net profit of 904/973/1.086 billion Hong Kong dollars.


First coverage given a "buy" rating. Taking into account comparable company analysis and discounted cash flow valuation, a target price of 20.2 Hong Kong dollars is assigned.


Risk warning: Significant changes in the company's franchise operation status; weakening domestic demand for imported tobacco leaves; climate affecting tobacco planting in Brazil; declining tobacco prices.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30